& Drug Administration (FDA) sent letters to manufacturers of over-the-counter (OTC) teething
products and also issued a warning to consumers to stop using products that
contain benzocaine on infants and small children. Marketed to temporarily
relieve a child’s teething pain, the agency said these OTC products pose a
“serious risk.” The FDA is taking steps to raise awareness of the risks
associated with the use of these products in young children and is threatening
regulatory action to remove these products from stores if companies fail to comply.
The FDA action also impacts prescription anesthetics, which will need to update
their product box warnings.